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Abstract
Background: The concept of spontaneous- or constitutive-activity has become widely accepted
and verified for numerous G protein-coupled receptors and this ligand-independent activity is also
acknowledged to play a role in some pathologies. Constitutive activity has been reported for the
mu opioid receptor. In some cases the increase in receptor basal activity was induced by chronic
morphine administration suggesting that constitutive activity may contribute to the development
of drug tolerance and dependence. Constitutively active mutants represent excellent tools for
gathering information about the mechanisms of receptor activation and the possible physiological
relevance of spontaneous receptor activity. The high basal level of activity of these mutants also
allows for easier identification of inverse agonists, defined as ligands able to suppress spontaneous
receptor activity, and leads to a better comprehension of their modulatory effects as well as
possible in vivo use.
Results: Cysteines 348 and 353 of the human mu opioid receptor (hMOR) were mutated into
alanines and Ala348,353 hMOR was stably expressed in HEK 293 cells. [35S] GTPγS binding
experiments revealed that Ala348,353 hMOR basal activity was significantly higher when compared to
hMOR, suggesting that the mutant receptor is constitutively active. [35S] GTPγS binding was
decreased by cyprodime or CTOP indicating that both ligands have inverse agonist properties. All
tested agonists exhibited binding affinities higher for Ala348,353 hMOR than for hMOR, with the
exception of endogenous opioid peptides. Antagonist affinity remained virtually unchanged except
for CTOP and cyprodime that bound the double mutant with higher affinities. The agonists
DAMGO and morphine showed enhanced potency for the Ala348,353 hMOR receptor in [35S]
GTPγS experiments. Finally, pretreatment with the antagonists naloxone, cyprodime or CTOP
significantly increased Ala348,353 hMOR expression.
Conclusion: Taken together our data indicate that the double C348/353A mutation results in a
constitutively active conformation of hMOR that is still activated by agonists. This is the first report
of a stable CAM of hMOR with the potential to screen for inverse agonists.
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The opioid receptors and endogenous opioid peptides
form a neuromodulatory system that plays a major role in
the control of nociceptive pathways. The opioid system
also modulates affective behavior, neuroendocrine physi-
ology, and controls autonomic functions such as respira-
tion, blood pressure, thermoregulation and
gastrointestinal motility. The receptors are targets for
exogenous narcotic opiate alkaloids that constitute a
major class of drugs of abuse [1]. Genes coding for δ, κ
and µ opioid receptor types have been identified and iso-
lated from different vertebrates. Analysis of their
sequences shows that the receptors belong to the G pro-
tein-coupled receptor (GPCR) superfamily. The three opi-
oid receptor types exhibit different pharmacological
profiles but all three mediate their cellular effects by first
activating heterotrimeric G-proteins of the inhibitory type
that negatively couple to adenylyl cyclase.
The delta opioid receptor was the first GPCR described as
able to modulate second messengers in the absence of an
agonist [2]. To date the concept of spontaneous- or consti-
tutive-activity has become widely accepted and verified
for numerous GPCRs [2-5], and this ligand-independent
activity is also suggested to play a role in some pathologies
[6]. For opioid receptors, constitutive activity has now
been reported not only for the delta [7-11] but also for the
kappa [12] and mu opioid receptors. In this latter case,
constitutive activity arose from spontaneous coupling to
endogenous G proteins [13,14] or was induced by chronic
morphine administration [15,16]. Some ligands like
naloxone and naltrexone were shown to act as antagonists
in untreated cells and to display inverse agonist properties
following morphine pretreatment [14-16]. Detection of
enhanced basal activity for mu opioid receptor densities
as low as 150 fmol/mg protein suggested that this activity
is of physiological relevance and may be involved in the
mechanisms underlying opioid tolerance [14].
Receptor mutagenesis has been widely used to probe
receptor activation mechanisms. Interestingly, some
mutations appeared to enhance basal activities of GPCRs.
Such mutations are believed to mimic agonist activity and
favor the active state of the receptor, thus facilitating pro-
ductive interaction with intracellular G proteins. These
mutant receptors are currently called Constitutively Active
Mutants (CAM) and exhibit several remarkable character-
istics [17-22]: (1) enhanced basal signaling activity, (2)
increased affinity for agonists, (3) enhanced agonist
potency and (4) increased level of expression upon cell
treatment with antagonists or inverse agonists. Several
CAMs have been described for the delta opioid receptor
[23-25]. Recently two mutants were also reported for the
mu opioid receptor. However both D164Q [26,27] and
T279K [28] mutations resulted in highly unstable mu
receptors that required addition of naloxone for stabiliza-
tion and detection of ligand binding.
In this work we characterized a mutant of the human mu
opioid receptor in which cysteine residues 348 and 353
were replaced by alanines. The resulting protein was sta-
bly expressed in HEK 293 cells at a pmol/mg membrane
protein level and exhibited all the characteristics of a con-
stitutively active mutant. Its potential use to screen for
inverse agonists was also established.
Results
Construction and stable expression of Ala348,353 hMOR in 
HEK 293 cells
We replaced cysteines 348 and 353 with alanine residues
in the human mu opioid receptor (hMOR). Alanine resi-
dues were preferred over serines to avoid introduction of
additional potential phosphorylation sites in the C-termi-
nal part of the receptor. Wild-type hMOR and the
Ala348,353 hMOR mutant were stably expressed in HEK 293
cells and compared.
Scatchard analysis indicated that both hMOR and
Ala348,353 hMOR displayed similar Kd values for the antag-
onist diprenorphine (Table 1) and that maximal expres-
sion levels were 1.50 ± 0.20 pmol/mg membrane protein
for Ala348,353 hMOR and 4.13 ± 0.26 pmol/ mg membrane
protein for the wild-type hMOR. Addition of a ligand in
the culture medium was not required to reach and main-
tain the high Ala348,353 hMOR expression level nor did this
level vary significantly with time for up to several months
of culture, corresponding to at least 25 passages.
Enhanced basal [35S] GTPγS incorporation in Ala348, 353 
hMOR
Data collected on several clones expressing hMOR or
Ala348,353 hMOR demonstrated that the double mutant
exhibited higher level of spontaneous [35S] GTPγS incor-
poration when compared to hMOR (25 ± 2 fmol/mg and
41 ± 2.5 fmol/mg respectively, Student's t test p < 0.001)
(Table 2). Moreover, since the expression level of
Ala348,353 hMOR was approximately three times lower
than the wild-type receptor, these results strongly suggest
that the mutant is a CAM receptor. We further investigated
[35S] GTPγS binding to probe the associated G proteins.
Coupling of opioid receptors is known to proceed
through inhibitory Gα proteins either pertussis toxin
(PTX) sensitive (Gi/o) or insensitive (Gz), the latter type
being absent from HEK 293 cells [29]. PTX treatment
abolishes interaction between the receptor and inhibitory
Gi/oα proteins by ADP ribosylation of a C-terminal
cysteine residue on the Gα protein. Following PTX treat-
ment, the [35S] GTPγS basal level of incorporation for
hMOR was reduced to the level observed in untransfected
HEK 293 cells (Figure 1A), denoting some spontaneousPage 2 of 12
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proteins under our experimental conditions. The high
[35S] GTPγS basal level of activity observed for the double
mutant was also reduced by PTX treatment though not to
the level observed in untransfected HEK 293 cells, suggest-
ing that spontaneous coupling of the mutant receptor
might also be mediated via PTX-insensitive Gα proteins
(Figure 1A) (see discussion). DAMGO-stimulated [35S]
GTPγS incorporation was completely abolished by PTX
treatment for both the wild type and the double mutant as
expected for receptors coupled to Gi/o α proteins (Figure
1B).
Pharmacological profile of Ala348,353 hMOR
CAM receptors are generally characterized by increased
agonist binding affinity while antagonist binding affinity
remains unaltered [17,18,20,21]. Consistent with this,
binding affinities of most agonists tested were increased
for Ala348,353 hMOR when compared to hMOR. Interest-
ingly, morphine and dermorphin affinities were increased
approximately 20-fold while we found no significant
change in affinities for the three endogenous peptides
dynorphin A, met-enkephalin and β-endorphin (Table 1).
On the other hand, binding affinities of several ligands
previously described as antagonists remained virtually
Table 1: Binding affinities for hMOR and Ala348,353 hMOR stably expressed in HEK 293 cells. Competition experiments were as described 
in the Experimental Procedures. Data are given as the mean ± S.E.M. from at least 3 independent experiments performed in triplicate. 
Statistical analysis was performed using Student's t test: the asterisks (*p < 0.05) refer to Ki values significantly different from 
corresponding Ki values for hMOR.
Ligand hMOR Ala348,353 hMOR
Ki(nM) Ki(nM) KiAla 348,353hMOR/KihMOR
Diprenorphine (Kd) 0.21 ± 0.03 0.41 ± 0.04
DAMGO 3.60 ± 0.44 1.13 ± 0.53* 0.32
Dermorphin 4.10 ± 1.70 0.26 ± 0.10* 0.06
Morphine 18.87 ± 4.76 0.88 ± 0.06* 0.05
β-endorphin 1.35 ± 0.42 2.45 ± 1.01 1.81
Dynorphin A 4.12 ± 0.85 1.59 ± 0.86 0.39
Met-enkephalin 2.78 ± 0.12 2.53 ± 0.58 0.91
Endomorphin 1 8.73 ± 2.66 0.51 ± 0.17* 0.06
Endomorphin 2 11.70 ± 3.90 1.79 ± 0.83* 0.15
Naloxone 3.63 ± 1.45 0.99 ± 0.25 0.27
Naltrexone 0.55 ± 0.22 0.17 ± 0.01 0.31
Naltrindole 5.07 ± 0.58 5.42 ± 0.56 1.06
Naloxonazine 2.91 ± 0.97 1.06 ± 0.23 0.36
Nalbuphine 2.28 ± 0.79 0.66 ± 0.05 0.29
CTOP 5.46 ± 0.70 0.32 ± 0.05* 0.06
Cyprodime 23.12 ± 7.22 1.83 ± 0.40* 0.08
Table 2: Efficacy and potency of opioid agonists for the stimulation of [35S] GTPγS binding in HEK 293 cells stably expressing hMOR or 
Ala348,353 hMOR. Agonist efficacy was calculated as the maximal difference between specific [35S] GTPγS binding in the presence and 
absence of agonist and is expressed in fmol/mg. EC50 values were obtained from curve fitting of dose response curves shown in Figure 
3. Receptor densities were 4.13 ± 0.26 and 1.5 ± 0.20 pmol/mg membrane protein for hMOR and Ala348,353 hMOR, respectively. Statistical 
analysis was performed using Student's t test: the asterisks (**p < 0.01, ***p < 0,001) refer to values significantly different from 
corresponding values for hMOR (Student's t test,)
Basal DAMGO Morphine
Efficacy EC50 Efficacy EC50
fmol/mg fmol/mg nM fmol/mg nM
hMOR 25 ± 2 98 ± 10 81 ± 2 48 ± 7 176 ± 2
(n = 32) (n = 10) (n = 5) (n = 3) (n = 3)
Ala348,353 hMOR 41 ± 2.5*** 58 ± 6 *** 9.1 ± 2.4** 48 ± 5 60 ± 2**
(n = 18) (n = 9) (n = 4) (n = 4) (n = 4)Page 3 of 12
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Comparison of hMOR and Ala348,353 hMOR [35S] GTPγS binding with or without PTX treatment. Basal (panel A) 
and DAMGO-induced (panel B) [35S] GTPγS incorporation were measured as described in the Experimental Procedures. Mem-
branes were prepared from HEK 293 cells stably expressing hMOR or Ala348,353 hMOR. Cells were treated with 100 ng/mL 
PTX for 20 h where indicated. DAMGO was added at a concentration of 10 µM. Data are given as the mean ± S.E.M. from at 
least 3 independent experiments performed in triplicate. Statistical analysis was performed using Student's t test to evaluate the 
effects of mutation (***, p < 0.001) or PTX-treatment (##, p < 0.01) on basal [35S] GTPγS incorporation (panel A) and of the 
effect of PTX-treatment (**, p < 0.01) on DAMGO-induced [35S] GTPγS incorporation (panel B).Page 4 of 12
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affinity for the antagonists CTOP and cyprodinie (Table
1). Interpretation for this latter observation remains
uncertain. Therefore modifications of ligand binding,
classically described for CAM receptors, were verified for
most, but not all opioid compounds.
Increased potency of agonist stimulated [35S] GTPγS 
incorporation
We measured [35S] GTPγS incorporation and determined
the EC50 values for DAMGO and morphine as prototypic
full and partial agonists, respectively (Table 2). EC50 val-
ues for Ala348,353 hMOR were decreased almost 10-fold for
DAMGO (9.1 ± 2.4 nM versus 81 ± 2 nM) and 3-fold for
morphine (60 ± 2 nM versus 176 ± 2 nM). These data
demonstrate that agonist potency is increased, as observed
for other CAM GPCRs [17,20]. DAMGO-induced maxi-
mal [35S] GTPγS incorporation was considerably lower at
Ala348,353 hMOR than the wild-type receptor while mor-
phine activated Ala348,353 hMOR and hMOR to a similar
extent (Table 2). When expressed as a percentage of stim-
ulation above basal levels (Figure 2), the maximal efficacy
of both ligands was reduced when compared to hMOR
(respectively 164 ± 6% versus 366 ± 23% for DAMGO and
164 ± 5% versus 205 ± 9% for morphine) due to the
higher basal activity level of the double mutant. Moreo-
ver, the lower level of expression of the mutant receptor
could also contribute to this observation since it directly
affects the extent of [35S] GTPγS incorporation [23]. Taken
together these results indicate that Ala348,353 hMOR is acti-
vated by agonists and that the extent of activation seems
to be ligand dependent.
Inverse agonism at Ala348,353 hMOR
Elevated basal activity of the receptors allows compounds
to be tested for intrinsic negative activity, also called
inverse agonism [5,6,30]. In order to identify ligands with
inverse agonist properties, several antagonists were tested
for their ability to decrease the basal level of [35S] GTPγS
incorporation on the Ala348,353 mutant. Under our experi-
mental conditions, all the tested compounds had statisti-
cally significant (Student's t test, p < 0.05) partial agonist
activity on hMOR with the exception of naloxone and nal-
trexone (Figure 3A). Partial agonist activity has been
observed for several opioid ligands originally described as
antagonists such as cyprodime [31], CTAP [14], TIPP and
Tic-deltorphine (Kieffer B.L. unpublished) as well as for
5HT4 ligands [32]. In contrast, this partial agonist activity
was not observed with Ala348,353 hMOR. Moreover
cyprodime and CTOP significantly reduced the level of
basal activity of Ala348,353 hMOR (89 ± 3% and 77 ± 5% of
control respectively, Student's t test p < 0.01). The EC50
values were 93 ± 3 nM and 64 ± 3 nM for CTOP and
cyprodime respectively (data not shown). These data sug-
gest that both ligands possess intrinsic inverse agonist
activity that is revealed at the CAM receptor (Figure 3B).
Upregulation of Ala348,353 hMOR expression
Addition of inverse agonists or antagonists to the cell cul-
ture medium was reported to increase the level of expres-
sion of CAM GPCRs by stabilizing their conformation
[19,20,27]. We therefore examined the effect of naloxone,
CTOP and cyprodime on the levels of expression of
hMOR and Ala348,353 hMOR. Expression levels measured
on intact cells using [3H] diprenorphine were 243 000 ±
28 000 receptors/cell for Ala348,353 hMOR and 546 000 ±
103 000 receptors/cell for hMOR prior treatment.
Naloxone and CTOP slightly increased hMOR expression
levels (145 ± 11% and 157 ± 20% respectively) while
cyprodime had no effect (103 ± 9%). In contrast Ala348,353
hMOR expression level was enhanced more than 2-fold in
the presence of alkaloid antagonists (257 ± 19% with
naloxone and 245 ± 20% with cyprodime, see Figure 4).
Importantly Kd values for [3H] diprenorphine were not
significantly altered by the various treatments (data not
shown). Therefore, although basal expression of the
mutant receptor is high, opioid antagonists increased the
number of receptors as previously observed for other
CAM GPCRs [19,20,27]. On the other hand, CTOP treat-
ment increased both mutant (182 ± 4%) and wild type
receptor (157 ± 20%) expression levels but failed to
induce a significantly higher expression level for Ala348,353
hMOR as compared to the wild type receptor (Figure 4,
see discussion). Receptor up-regulation by naloxone and
cyprodime was detectable using intact cells treated for 48
hours and was also observed on membranes prepared
from these cells (data not shown).
Chronic treatment with morphine
Finally, because chronic morphine treatment was
reported to increase basal activity of mu receptors in HEK
293 [33] and GH3 [16] cells, we treated our HEK 293 cells
stably expressing hMOR or Ala348,353 hMOR with 10 µM
morphine for 48 h. Under our experimental conditions,
morphine pretreatment did not modify the basal level of
[35S] GTPγS incorporated in hMOR or Ala348,353 hMOR.
Moreover, we could not detect any increase of the maxi-
mal inverse agonist efficacy of CTOP and cyprodime fol-
lowing chronic morphine treatment of cells expressing
either hMOR or Ala348,353 hMOR (data not shown). A pos-
sible explanation for this discrepancy could be a combina-
tion of factors such as cell type (HEK 293 cells versus GH3
cells), duration of morphine exposure (48 h versus 16 h in
HEK 293 cells) and a lack of sensitivity of the detection
method ([35S] GTPγS performed on crude membrane
preparation without prior G protein isolation). Neverthe-
less, in agreement with previous reports, we observed a
significant reduction of [35S] GTPγS incorporation
following DAMGO stimulation for both hMOR (339 ±Page 5 of 12
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DAMGO and morphine-stimulated [35S] GTPγS binding at hMOR and Ala348,353 hMOR. Increasing concentrations 
of DAMGO and morphine (10-10 to 10-4 M) were used to stimulate [35S] GTPγS binding. Panel A: DAMGO at hMOR (■) or at 
Ala348,353 hMOR (▼). Panel B: morphine at hMOR (◆) or Ala348,353 hMOR (▲). Data are given as the mean ± S.E.M. from at 
least 3 independent experiments performed in triplicate.Page 6 of 12
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Effect of antagonists on the incorporation of [35S] GTPγS binding in membranes expressing hMOR and 
Ala348,353 hMOR. [35S] GTPγS incorporation was measured as described in the Experimental Procedures. Panel A: mem-
branes prepared from HEK 293 cells stably expressing hMOR. Panel B: membranes prepared from HEK 293 cells stably 
expressing Ala348,353 hMOR. All ligands were used at a concentration of 10 µM. Incorporation is expressed as percent variation 
over [35S] GTPγS binding in the absence of agonist. Data are given as the mean ± S.E.M. from 3 (except naloxone, CTOP and 
cyprodime where n = 5) independent experiments performed in triplicate. Statistical analysis was performed using Student's t 
test, *p < 0.05, **p < 0.01 compared to basal [35S] GTPγS.Page 7 of 12
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Ala348,353 hMOR (120 ± 5% versus 153 ± 13%, Student's t
test p < 0.05, data not shown) presumably reflecting
receptor desensitization [16,33].
Discussion
In this paper, we describe a mutant of the human mu opi-
oid receptor in which cysteine residues 348 and 353 have
been replaced by alanines and we demonstrate that this
mutant receptor is constitutively active, based on charac-
teristic properties previously described for other CAM
GPCRs.
The most decisive criterion used to define a CAM receptor
is enhanced basal activity. Ala348,353 hMOR exhibited
basal [35S] GTPγS incorporation at least 1.5 times higher
than wild-type hMOR under conditions where the mutant
receptor was expressed at levels almost three times lower
than the wild-type receptor. This strongly indicates that
the Ala348,353 mutant spontaneously activates G proteins
more efficiently than the wild-type receptor, and is further
supported by the PTX sensitivity of this activity.
Noticeably, for the Ala348,353 hMOR mutant, PTX treat-
ment did not entirely reduce basal [35S] GTPγS incorpora-
tion to the level observed in non-transfected cells. One
explanation could be that the mutant receptor is partially
coupled to the inhibitory PTX-insensitive Gzα protein, as
previously shown for mu receptors [29]. Gzα subunits,
however, appear to be absent in HEK 293 cells [29]. Alter-
natively, one may speculate that the constitutive confor-
mation of the mutant receptor may exhibit broader G
protein selectivity allowing it to interact with Gα subunits
for which coupling remains to be established. This could
be of importance if chronic administration of drugs does
indeed increase basal activity of the mu receptor [16,33].
A residual [35S] GTPγS incorporation following PTX treat-
ment could also be observed for the CAM T279K mu
receptor [28].
CAMs generally display enhanced agonist binding affin-
ity, supposedly because a large fraction of the receptors are
in a G protein-precoupled active state [20,21]. Ala348,353
hMOR satisfied this criterion for most of the ligands
tested. One notable exception was the modest changes in
affinity showed by the endogenous opioid peptides com-
pared to alkaloids or synthetic peptides. Dynorphin A
showed only a tendency to an increase in binding affinity
for Ala348,353 hMOR, while β-endorphin and met-
enkephalin affinities remained unchanged. Interestingly,
in another set of experiments, we forced receptor interac-
tion with Giα proteins by fusing hMOR to Gi1α or Gi2α. As
expected, binding affinities were increased for most ago-
nists. However, β-endorphin and met-enkephalin affini-
ties remained unchanged while dynorphin A affinity
increased for the Gi2α-hMOR fusion only [34]. Endog-
enous opioid peptides, therefore, could be less sensitive to
the coupling status of the receptor compared to other
exogenous or synthetic opioids. An implication of this
observation is that the putative modifications of mu opi-
oid receptor coupling following chronic morphine sug-
gested by some authors [16,33], may be of little
consequence to endogenous opioid binding.
Because of its high stable expression and CAM properties,
Ala348,353 hMOR represents a unique tool for identifica-
tion of compounds with inverse agonist properties. Our
analysis of a number of mu receptor antagonists revealed,
for the first time, negative functional activity for CTOP
and cyprodime (see Figure 3B). Previous studies suggested
that the irreversible antagonist β-CNA could inhibit the
spontaneous activity of the wild-type mu opioid receptor
[13]. Also inverse agonist properties were reported for β-
CNA as well as naloxone and naltrexone following
chronic exposure to opioid agonists [14,16]. Our data
highlight two novel antagonists as mu opioid inverse ago-
nists, and more will likely be discovered in the future.
Both DAMGO and morphine exhibited enhanced potency
for Ala348,353 hMOR as expected for agonists interacting
with a CAM. Enhanced potency to stimulate [35S] GTPγS
binding can be correlated to the higher affinity observed
for both agonists towards the Ala348,353 mutant receptor.
Higher potency for agonists has also been described for
CAMs of α1a-, α1b-[17,20] as well as α2A-adrenergic [21] orβ2-adrenergic receptors [18] and, more recently, for a
CAM of the 5-HT4(a) receptor [35]. Interestingly, all
agonists tested increased ERK2 (p44) phosphorylation
upon binding to Ala348,353 hMOR to levels higher than the
wild type receptor, suggesting that the double Ala 348,
353 Cys mutation alters both Gα- and Gβγ-dependent sig-
naling pathways (data not shown).
Enhancement of expression levels following receptor
exposure to a ligand is another typical feature of CAM
GPCRs. Accordingly, Ala348,353 hMOR was significantly
upregulated upon naloxone or cyprodime treatment.
Interestingly, however, basal expression of the Ala348,353
hMOR receptor was relatively high and easily detectable
in the absence of any ligand in the culture medium.
Structural instability seems to be a frequent characteristic
of CAMs, but this was not obvious in our case. Two CAMs
of the mu opioid receptor were reported previously, with
D164Q [26,27] and T279K [28] mutations located in the
transmembrane domains III and VI, respectively. Both
mutants are highly unstable and require the presence of
the antagonist naloxone in the cell culture medium for
stabilization and pharmacological detection [27,28]. One
explanation for the relative stability of Ala348,353 hMOR
may lie in the C-terminal location of the mutations down-
stream from helix VIII that is postulated on the basis ofPage 8 of 12
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structure [36]. The mutated cysteines are not likely to be
directly involved in the formation of the ligand binding
pocket or critical in maintaining the three-dimensional
architecture of the helical protein core. Ala348,353 hMOR
expression was nevertheless upregulated upon cell treat-
ment with naloxone, cyprodime or CTOP. According to
the extended ternary complex model, CAMs are expected
to favor the partially activated receptor state (R*) that is
very often unfavorable in terms of energy and results in
some structural instability [19,37]. Antagonists as well as
inverse agonists on the other hand bind preferentially to
the inactive R state of the receptor and stabilize it. There-
fore the increased number of double mutant receptors
observed following naloxone, cyprodime or CTOP treat-
ment may reflect the shift of the equilibrium towards the
R form resulting in a larger proportion of structurally
more stable receptors. However it could also reflect the
blocking of constitutive internalization and down regula-
tion as suggested for the D164Q mutant [27] and
observed for the wild-type hMOR [27,38]. Interestingly,
CTOP treatment increased Ala348,353 hMOR expression
level to a lesser extent than either naloxone or cyprodime.
Also the mutant receptor expression level following CTOP
Upregulation of hMOR and Ala348,353 hMOR expression upon ligand pretreatment of the cellsFigure 4
Upregulation of hMOR and Ala348,353 hMOR expression upon ligand pretreatment of the cells. Saturation experi-
ments using [3H]diprenorphine on intact HEK 293 cells stably expressing hMOR (checked bars) or Ala348,353 hMOR (black bars) 
following cell treatment with naloxone, cyprodime or CTOP 1 mM for 48 h as described in the Experimental Procedures. Data 
are given as the mean ± S.E.M. from at least 4 independent experiments. Statistical analysis was performed using Student's t test 
to compare upregulation at wild-type and mutant receptors, ** p < 0.01 compared to hMOR.Page 9 of 12
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observed for the wild-type receptor. This is in contrast
with the larger number of Ala348,353 hMOR receptors
detected following treatment with the membrane perme-
able alkaloids naloxone and cyprodime compared to wild
type. These results suggest that stabilization, by alkaloids,
of a receptor folding intermediate during its transport to
the plasma membrane may also contribute to the upregu-
lation of expression observed for the double mutant.
Indeed such a chaperone activity resulting in an increased
cell surface expression of rat mu opioid receptor mutants
was recently reported [39]. Moreover proper folding of the
polypeptide has been demonstrated to be of crucial
importance for cell surface expression in several cases [40]
including the human delta opioid receptor expressed in
HEK 293 cells [41].
Mutations of the C-terminal cysteine residues have
already been reported for several GPCRs [35,42-44]. At
present the influence of C-terminal cysteine mutations on
the signaling efficiency seems receptor type-dependent
[35,42-44]. Mutation of the conserved cysteine residues
328/329 into serines in the 5-HT(4a) receptor, a receptor
coupled to Gsα, led to a CAM [35]. Using a random muta-
genesis screen a delta opioid receptor mutant in which
cysteine 328 was replaced by an arginine residue was
recently identified as having constitutive activity [25].
Ala348,353 hMOR is the third example of a receptor mutant
whose constitutive activity is intertwined with C-terminal
cysteine replacement. The two cysteine residues mutated
in hMOR are located in well conserved positions (cysteine
353 is conserved in the 5-HT4a receptor and cysteine 348
is equivalent to cysteine 328 in the delta opioid receptor)
suggesting a common role at least in some GPCRs. The
mechanism underlying the appearance of constitutive
activity has been correlated with the palmitoylation state
of the cysteine residues in the case of the 5-HT(4a) receptor
[35] and preliminary data indicate that hMOR is palmi-
toylated when expressed in baculovirus-infected Sf9 cells
(Massotte D., unpublished results). However other expla-
nations can be envisaged that would involve the dynamic
regulation of the receptor such as a mutation-induced
modulation of its phosphorylation state [45]. We are cur-
rently further investigating the cysteine residue(s) respon-
sible for Ala348,353 hMOR constitutive activity as well as
the underlying mechanisms.
Conclusions
We have established that the mutation of cysteines 348
and 353 into alanines resulted in a mutant hMOR recep-
tor whose conformation satisfies criteria known to define
a CAM. This is also the first mutant of this type described
for the mu opioid receptor that does not require the addi-
tion of a ligand to the culture medium to be stably
expressed at a pmol/mg membrane protein level. These
combined properties suggest that this mutant receptor is
of potential use for inverse agonist screening. This is
indeed the case since Ala348,353 hMOR high basal activity
led for the first time to the identification of CTOP and
cyprodime as inverse agonists and will undoubtedly trig-
ger the discovery of others. Identification of such ligands
offers new tools to probe the spontaneous activity of the
wild-type mu opioid receptor upon chronic administra-
tion of drugs. This CAM also provides an interesting
model that mimics spontaneous receptor activity and
could help to address the mechanisms underlying the
development of drug tolerance and dependence.
Methods
Materials
[3H] Diprenorphine was purchased from Amersham
(Arlington Heights, IL, USA) and [35S] GTPγS (specific
activity 1250 Ci/mmol) from Perkin Elmer Life Science
(Boston, Ma, USA). Ligands were from Sigma (St Louis,
MO, USA). All materials for tissue culture were supplied
by Life Technologies, Inc. (Paisley, U.K).
Construction of the mutated receptor
The cDNA encoding the human mu opioid receptor in
pcDNA3 was used as a template to generate a mutant in
which C348A and C353A mutations were introduced
using PCR. The oligonucleotide A containing a KpnI site
(underlined) 5'-ATTGGGGTACCCCATGGACAG-
CAGCGCTGCC-3' and the oligonucleotide 5'-
GAACTCTCTGAAGGCTCGTTTGAA-3' were used to gen-
erate the C348A mutation. The oligonucleotide 5'-TTCA-
GAGAGTTCGCTATCCCAA-3' and the oligonucleotide B
containing a KpnI site (underlined) 5'-CTCGGGTACCT-
TAGGGCAACGGAGCAGTTTCTGC-3' were used to gener-
ate the C353A. The resulting PCR products were used as
templates for a second amplification by PCR using oligo-
nucleotides A and B to generate the double mutant
Ala348,353 hMOR that was introduced in the KpnI site of
pcDNA3 and verified by sequencing.
Cell culture and generation of stable cell lines
HEK 293 cells were maintained in MEM containing 10%
(v/v) fetal calf serum and 2 mM glutamine. Cells plated in
10 cm2 dishes at semi-confluence were transfected with
hMOR, or Ala348,353 hMOR using calcium phosphate co-
precipitation. Individual clones were isolated and
expanded in the presence of 100 µg/mL geneticin. Where
indicated, cells were treated with 100 ng/ml PTX for 20 h
before harvesting.
Receptor expression following cell treatment with 
antagonists
HEK 293 cells stably expressing hMOR or Ala348,353 hMOR
were treated with 1 µM naloxone, cyprodime or CTOP for
48 h with one medium exchange after 24 h. Cells werePage 10 of 12
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sucrose, resuspended in 50 mM Tris, pH 7.4 containing
320 mM sucrose and counted. Saturation analysis was
performed on intact cells under conditions similar to
those described for membranes (see below). 0.2% BSA
was added to all buffers when CTOP-treated cells were
used.
Preparation of membranes
Cells were collected, washed twice with PBS and stored at
-80°C in PBS containing 320 mM sucrose. Cell pellets
were resuspended in ice cold 50 mM Tris-HCl, 1 mM
EDTA, pH 7.4, disrupted using a glass homogenizer and
centrifuged at 2000 g for 10 min. The pellet was homoge-
nized in ice cold 50 mM Tris-HCl, 1 mM EDTA, pH 7.4
and centrifuged at 1000 g for 5 min. Both supernatants
were combined and ultracentrifuged at 100 000 g for 40
min at 4°C. The pellet was resuspended in 50 mM Tris-
HCl, 1 mM EDTA, 320 mM sucrose, pH 7.4 then homog-
enized through a 26-gauge needle and stored in aliquots
at -80°C before use.
Saturation and competition analysis
For each assay 10 µg of membrane protein was incubated
in 50 mM Tris-HCl, pH 7.4 with the appropriate ligands
in a final volume of 500 µl for 30 min at 22°C. For all sat-
uration experiments [3H] diprenorphine was used in a
0.05–6.4 nM range and naloxone was used at 2 µM to
determine non-specific binding. For all competition
experiments [3H] diprenorphine was used at 1 nM and the
competing ligand in a 10-5–10-13 M range. In both cases,
incubation was terminated by rapid filtration on GF/B fil-
ters treated with 0.1% (vol/vol) polyethylenimine fol-
lowed by three washes with ice-cold 50 mM Tris-HCl, pH
7.4 on a Brandell cell harvester. Bound radioactivity was
determined by scintillation counting. Scatchard and com-
petition analyses were performed using the EBDA/Ligand
program (G.A. McPherson, Biosoft, Cambridge, UK).
[35S] GTPγS binding studies
Stock [35S] GTPγS was diluted to 50 nM in 10 mM tricine
pH 7.4, 10 mM DTT. Aliquots were stored at -80°C. For
each assay, 10 µg of membrane protein was incubated in
50 mM Hepes, pH 7.4, 5 mM MgCl2, 100 mM NaCl, 1
mM EDTA, 1 mM DTT, 0.1% (wt/vol) BSA, 10 µM GDP,
0.1 nM [35S] GTPγS and the appropriate ligand, in a final
volume of 200 µl for 2 h at 4°C. Non specific binding was
determined in the presence of 10 µM GTPγS and basal
binding was assessed in the absence of agonist. Incuba-
tion was terminated by rapid filtration on H2O presoaked
GF/B filters followed by three washes with cold 50 mM
Tris-HCl pH 7.4, 5 mM MgCl2, 50 mM NaCl using a Bran-
dell cell harvester. Bound radioactivity was determined by
scintillation counting. EC50 values were determined using
Prism software (GraphPad, San Diego, CA, USA).
Abbreviations
GPCR: G protein-coupled receptor, DAMGO: [D-Ala2, N-
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